1Mckham G, Drachman D, Fostein M, et al. Diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the department of health[J]. Neurology, 1984,34:939～944.
2Tariot PN, Mack JL, Patterson MB, et al. The behavior rating scale for dementia[J]. Am J Psychiatry, 1995,152(9): 1349～1357.
2Rogers J, Luber-Narod J, Styren SD,et al. Expression of immune sys- tem-associated antigens by ceils of the human central nervous system : relationship to the pathology of Alzheimers disease. Neurobiol Aging, 1988,9:339-349.
3in tVeld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflam- matory drugs and the risk of Alzheimer "s disease. N Engl J Med, 2001,345 : 1515-1521.
4Akiyama H, Bragger S, Barnum S, et al. Inflammation and alzheimer's. Neurobiol Aging, 2000,21 : 383 -421.
5Luein KM ,Wyss-Coray T. Immune activation in brain aging and neu- rodegeneration : too much or too little? Neuron,2009,64 : 110-122.
6Falsig J,van Beek J,Hermmm C,et al. Molecular basis for detection of in- vading pathogens in the brain. J Neurosci Res,2008,86:1434-1447.
7Salminen A, Ojala J, Kauppinen A, et al. Inflammation in Alzheimers disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol,2009 ,87 :181-194.
8Martinon F, Mayor A,Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol,2009 ,27 :229-265.
9Maezawa I,Zimin PI, Wulff H, et al Amyloid-beta protein oligomer at low nanomolar concentrations activales microglia and induces microgli- al neurotoxicity. J Biol Chem,2011,286 :3693-3706.
10Daly JT, Kotwal GJ. Pro-inflammatcry complement activation by the A beta peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein. Neurobiol Aging, 1998,19:6194527.
